Business
Exscientia partnership with GT Apeiron
Exscientia partnership with GT Apeiron.
About this update from Frontier Ip Group Plc
[{"type":"text","content":"\n \nRNS Number : 1681C Frontier IP Group plc 14 June 2019 \n\nRNS Reach\nAIM: FIPP\n14 June 2019\n \n \nFrontier IP Group Plc\n(\"Frontier IP\" or the \"Group\")\n \nPortfolio news - Exscientia expands international collaborations with AI drug discovery partnership with GT Apeiron Therapeutics\n \nFrontier IP, a specialist in commercialising university intellectual property, is pleased to note the following announcement from portfolio company Exscientia (\"Exscientia\" or the \"Company\"), a world leader in artificial intelligence (\"AI\") drug discovery, that it has entered into a drug-discovery partnership with GT Apeiron Therapeutics (\"GT Apeiron\"). \n \nGT Apeiron is a Shanghai-headquartered biotechnology drug-discovery platform launched with US$27 million backing from GT Healthcare Capital Partners (\"GT Healthcare\"), a life sciences-focused private equity partnership. GT Healthcare is also an investor in Exscientia.\n \nAs part of the agreement, Exscientia is entitled to become a shareholder in GT Apeiron as well as receiving milestones and royalties based on the clinical and commercial success of each programme. \n \nGT Healthcare invested in Exscientia as part of a Series B financing round, which raised US$26 million to scale up the Company's pipeline and advance selected programmes towards clinical development. Further details were announced by Frontier IP on 7 January 2019. \n \nExscientia's existing partnerships include collaborations with Celgene, GSK, Roche, Sanofi and Evotec. \n \nFrontier IP holds a 3.32 per cent stake in the Company. \n \nExscientia statement in full:\n \n \nEXSCIENTIA EXPANDS INTERNATIONAL COLLABORATIONS WITH SHANGHAI-HEADQUARTERED GT APEIRON THERAPEUTICS\n \nFIRM ENTERS A MULTI-TARGET AI DRUG DISCOVERY PARTNERSHIP WITH INITIAL FOCUS ON ONCOLOGY\n \nOxford, UK, June 2019: Exscientia, a world-leading Artificial Intelligence (AI)-driven drug discovery company, announced today that it has entered an AI drug discovery partnership with Shanghai-headquartered GT Apeiron Therapeutics (\"GT Apeiron\"). \n \nThe collaboration will use Exscientia's full-stack AI drug discovery capabilities and GT Apeiron's proprietary technologies to accelerate the development of novel drugs via new pathways to tackle high impact therapeu...